HCC in MASLD: radiological appearance, diagnosis and treatment

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), are emerging as leading causes of hepatocellular carcinoma (HCC) development. This has important implications for evaluating patients with these conditions, including the potential for early diagnosis through screening techniques. Imaging techniques for the noninvasive diagnosis of HCC in the context of MASLD also present unique considerations. Notably, HCC development in patients without cirrhosis is more frequent in MASLD compared to other chronic liver disease etiologies. Moreover, the presence of liver steatosis, a common feature in MASLD patients, can modify the radiological appearance of the liver, giving HCC in MASLD/MASH uncommon imaging characteristics. Additionally, certain histological subtypes, particularly the steatohepatitic HCC, are more prevalent in MASLD/MASH, which may influence both diagnostic strategies and therapeutic decisions in these patients. This review article focuses on the radiological characteristics of HCC developed in patients with MASLD/MASH. It specifically addresses the roles of screening and surveillance, the radiological features of HCC in MASLD/MASH, the histological subtypes associated with these conditions, and the impact of imaging on treatment decisions. Finally, a brief summary of future directions and the role of new technologies in HCC diagnosis within the context of MASLD is provided.

Keywords

Hepatocellular carcinoma / MASLD / NAFLD / steatosis

References

[1] Oh JH.The latest global burden of liver cancer: a past and present threat.Clin Mol Hepatol2023;29:355-7 PMCID:PMC10121295

[2] Younossi ZM,Paik JM,Van Dongen C.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023;77:1335-47 PMCID:PMC10026948

[3] Singal AG,Nahon P.Epidemiology and surveillance for hepatocellular carcinoma: new trends.J Hepatol2020;72:250-61 PMCID:PMC6986771

[4] Dyson J,Chattopadyhay D.Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team.J Hepatol2014;60:110-7

[5] Mittal S,Sada YH.Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2016;14:124-31.e1 PMCID:PMC4690789

[6] Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[7] Singal AG,Yarchoan M.AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.Hepatology2023;78:1922-65 PMCID:PMC10663390

[8] Singal AG.Rational HCC screening approaches for patients with NAFLD.J Hepatol2022;76:195-201 PMCID:PMC8688224

[9] Samoylova ML,Roberts JP.Predictors of ultrasound failure to detect hepatocellular carcinoma.Liver Transpl2018;24:1171-7

[10] An JY,Cunha GM.Abbreviated MRI for hepatocellular carcinoma screening and surveillance.Radiographics2020;40:1916-31 PMCID:PMC7714535

[11] Kim DH,Choi MH.Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC.J Hepatol2024;81:461-70

[12] Gupta P,Patel A,Sharma V.Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis.J Hepatol2021;75:108-19

[13] Huang DQ,Liau J.Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: a prospective study.Aliment Pharmacol Ther2022;55:820-7 PMCID:PMC9762322

[14] Soundararajan R,Gupta P.Diagnostic performance of abbreviated MRI for HCC detection in patients with non-alcoholic fatty liver disease.J Clin Exp Hepatol2024;14:101276 PMCID:PMC10709163

[15] Best J,Sowa JP.GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2020;18:728-35.e4

[16] Cerrito L,Ainora ME,Gasbarrini A.Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: the prognostic role of liver stiffness measurement.Cancers2023;15:637 PMCID:PMC9913338

[17] Cannella R,Sartoris R,Vilgrain V.Adherence to LI-RADS and EASL high-risk population criteria: a systematic review.Hepatology2023;77:1958-67

[18] Cannella R,Brancatelli G.ESR Essentials: diagnosis of hepatocellular carcinoma-practice recommendations by ESGAR.Eur Radiol2024;34:2127-39 PMCID:PMC10957713

[19] CT/MRI LI-RADS® v2018 CORE. Available from: https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf. [Last accessed on 18 Dec 2024].

[20] Ludwig DR,Cannella R.Expanding the liver imaging reporting and data system (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria.HPB2019;21:1697-706

[21] Fraum TJ,Ludwig DR.Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.Eur Radiol2020;30:996-1007

[22] Kim DH,Kim DW.Combined hepatocellular-cholangiocarcinoma: magnetic resonance imaging features and prognosis according to risk factors for hepatocellular carcinoma.J Magn Reson Imaging2021;53:1803-12

[23] Desai A,Lai JP.Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review.World J Hepatol2019;11:1-18 PMCID:PMC6354117

[24] Di Martino M,Bosco S.Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings.Eur Radiol2014;24:1446-54

[25] Gaddikeri S,Wang CL.Hepatocellular carcinoma in the noncirrhotic liver.AJR Am J Roentgenol2014;203:W34-47

[26] Mamone G,Carollo V.Imaging of primary malignant tumors in non-cirrhotic liver.Diagn Interv Imaging2020;101:519-35

[27] Winston CB,Fong Y,Panicek DM.Hepatocellular carcinoma: MR imaging findings in cirrhotic livers and noncirrhotic livers.Radiology1999;210:75-9

[28] Lafitte M,Soyer P.MDCT features of hepatocellular carcinoma (HCC) in non-cirrhotic liver.Diagn Interv Imaging2016;97:355-60

[29] Brancatelli G,Grazioli L.Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents.Radiology2002;222:89-94

[30] Park EJ,Choi SH.Imaging features of hepatocellular carcinoma in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: a systematic review and meta-analysis.Abdom Radiol2022;47:2089-98

[31] Cannella R,Sartoris R.Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent.Diagn Interv Imaging2021;102:735-42

[32] Thompson SM,Ehman EC.Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.Br J Radiol2018;91:20180345 PMCID:PMC6319849

[33] WHO Classification of Tumours Editorial Board. Digestive system tumours. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Digestive-System-Tumours-2019. [Last accessed on 18 Dec 2024].

[34] Mulé S,Tenenhaus A.Multiphase liver MRI for identifying the macrotrabecular-massive subtype of hepatocellular carcinoma.Radiology2020;295:562-71

[35] Salomao M,Brown RS Jr,Lefkowitch JH.Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.Am J Surg Pathol2010;34:1630-6

[36] Trapani L,Hobeika C.Pathological overview of steatohepatitic hepatocellular carcinoma in a surgical series.Histopathology2023;83:526-37

[37] Yamaoka K,Kinowaki K.Clinicopathological assessment of steatohepatitic hepatocellular carcinoma.Clin Res Hepatol Gastroenterol2022;46:101799

[38] Jain D,Kumaran V.Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India.Arch Pathol Lab Med2013;137:961-6

[39] Cannella R,Beaufrère A.Imaging features of histological subtypes of hepatocellular carcinoma: implication for LI-RADS.JHEP Rep2021;3:100380 PMCID:PMC8603197

[40] Mulé S,Pregliasco AG.MRI features associated with HCC histologic subtypes: a western American and European bicenter study.Eur Radiol2023;33:1342-52

[41] Auer TA,Fehrenbach U.Gd-EOB MRI for HCC subtype differentiation in a western population according to the 5(th) edition of the World Health Organization classification.Eur Radiol2023;33:6902-15 PMCID:PMC10511376

[42] Inui S,Tanahashi Y.Steatohepatitic hepatocellular carcinoma: imaging findings with clinicopathological correlation.Clin Radiol2021;76:160.e15-25

[43] Chen K,Dong Y.Contrast-enhanced imaging features and clinicopathological investigation of steatohepatitic hepatocellular carcinoma.Diagnostics2023;13:1337 PMCID:PMC10093104

[44] Park JH,Kim MJ.Steatotic hepatocellular carcinoma: association of MRI findings to underlying liver disease and clinicopathological characteristics.Liver Int2023;43:1332-44

[45] Faure A,Cannella R.Imaging and prognostic characterization of fat-containing hepatocellular carcinoma subtypes.Radiol Med2024;129:687-701

[46] Tan DJH,Lin SY.Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.Lancet Oncol2022;23:521-30 PMCID:PMC9718369

[47] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[48] American College of Radiology^TM. Liver imaging reporting & data system (LI-RADS®). Available from: https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/LI-RADS. [Last accessed on 24 Apr 2025].

[49] Nguyen N,Trillaud H.Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver disease.Liver Int2022;42:905-17

[50] Koh YX,Liew YX.Liver resection for nonalcoholic fatty liver disease-associated hepatocellular carcinoma.J Am Coll Surg2019;229:467-78.e1

[51] Cauchy F,Dokmak S.Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome.Br J Surg2013;100:113-21

[52] Chin KM,Cheong CK.Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a meta-analysis and review of current literature.HPB2021;23:1164-74

[53] Younossi Z, Stepanova M, Ong JP, et al; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019;17:748-55.e3.

[54] Burgio M, Garzelli L, Cannella R, Ronot M, Vilgrain V. Hepatocellular carcinoma: optimal radiological evaluation before liver transplantation.Life2023;13:2267 PMCID:PMC10744421

[55] Wong CR,Nguyen MH,Lim JK.Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.Aliment Pharmacol Ther2017;46:1061-9

[56] Reddy SK,Chen HW.Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.Hepatology2012;55:1809-19

[57] Haldar D, Kern B, Hodson J, et al; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. J Hepatol 2019;71:313-22. PMCID:PMC6656693

[58] Foerster F,Müller L.NAFLD-driven HCC: safety and efficacy of current and emerging treatment options.J Hepatol2022;76:446-57

[59] Pfister D,Pinyol R.NASH limits anti-tumour surveillance in immunotherapy-treated HCC.Nature2021;592:450-6 PMCID:PMC8046670

[60] Pal Chaudhary S,Chase ML.Resection of NAFLD/NASH-related hepatocellular carcinoma (HCC): clinical features and outcomes compared with HCC due to other etiologies.Oncologist2023;28:341-50 PMCID:PMC10078904

[61] Younossi ZM,Henry L.Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.Hepatology2015;62:1723-30

[62] Molinari M,Samra PB.Hepatic resection for hepatocellular carcinoma in nonalcoholic fatty liver disease: a systematic review and meta-analysis of 7226 patients.Ann Surg Open2021;2:e065 PMCID:PMC10455059

[63] Koh B,Wang M,Ng CH.Application of artificial intelligence in the diagnosis of hepatocellular carcinoma.egastro2023;1:e100002

[64] Okanoue T,Shima T.Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis.Hepatol Res2023;53:1213-23

[65] Sarkar S,Ly C.A machine learning model to predict risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease.Gastro Hep Adv2024;3:498-505 PMCID:PMC11307858

[66] Kawka M,Jiao LR.Artificial intelligence in the detection, characterisation and prediction of hepatocellular carcinoma: a narrative review.Transl Gastroenterol Hepatol2022;7:41 PMCID:PMC9468986

[67] Ghosh S,Alim M,Bhat M.Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment.Gut2025;74:295-311 PMCID:PMC11874365

[68] Martinino A,Chatterjee S.Artificial intelligence in the diagnosis of hepatocellular carcinoma: a systematic review.J Clin Med2022;11:6368 PMCID:PMC9655417